文章摘要
李洁冰,田振峰,毕伟东,梁丙寅,张 弛,张 斌.通滞苏润江胶囊联合塞来昔布对早期膝骨关节炎患者血清炎症因子和疼痛介质的影响[J].,2024,(3):578-581
通滞苏润江胶囊联合塞来昔布对早期膝骨关节炎患者血清炎症因子和疼痛介质的影响
Effects of Tongzhi Surunjiang Capsules Combined with Celecoxib on Serum Inflammatory Factors and Pain Mediators in Patients with Early Knee Osteoarthritis
投稿时间:2023-06-07  修订日期:2023-06-28
DOI:10.13241/j.cnki.pmb.2024.03.034
中文关键词: 通滞苏润江胶囊  塞来昔布  早期膝骨关节炎  炎症因子  疼痛介质
英文关键词: Tong zhi su run capsules  Celecoxib  Early knee osteoarthritis  Inflammatory factors  Pain mediator
基金项目:河北省卫生健康委科研基金项目(20181014)
作者单位E-mail
李洁冰 石家庄市人民医院骨科 河北 石家庄 050000 13931181551@163.com 
田振峰 石家庄市人民医院骨科 河北 石家庄 050000  
毕伟东 石家庄市人民医院骨科 河北 石家庄 050000  
梁丙寅 石家庄市人民医院骨科 河北 石家庄 050000  
张 弛 石家庄市人民医院骨科 河北 石家庄 050000  
张 斌 石家庄市人民医院骨科 河北 石家庄 050000  
摘要点击次数: 102
全文下载次数: 79
中文摘要:
      摘要 目的:观察通滞苏润江胶囊联合塞来昔布对早期膝骨关节炎(KOA)患者血清炎症因子和疼痛介质的影响。方法:选择2021年6月-2022年12月期间石家庄市人民医院收治的早期KOA患者80例,采用随机数字表法将患者分为对照组(塞来昔布,40例)和观察组(通滞苏润江胶囊联合塞来昔布,40例)。对比两组疗效、疼痛视觉模拟评分(VAS)、西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评分、炎症因子和疼痛介质。结果:观察组临床总有效率高于对照组(P<0.05)。两组治疗1个月后VAS、WOMAC评分下降,且观察组低于对照组同时间点(P<0.05)。两组治疗1个月后肿瘤坏死因子-α(TNF-α)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)下降,且观察组低于对照组同时间点(P<0.05)。两组治疗1个月后前列腺素E2(PGE2)、P物质(SP)下降,且观察组低于对照组同时间点(P<0.05)。两组不良反应发生率对比未见统计学差异(P>0.05)。结论:塞来昔布和通滞苏润江胶囊联合治疗早期KOA患者,可缓解疼痛,提高临床治疗效果,改善关节功能,同时还可改善血清炎症因子和疼痛介质水平。
英文摘要:
      ABSTRACT Objective: To observe the effects of Tongzhi surunjiang capsules combined with celecoxib on serum inflammatory factors and pain mediators in patients with early knee osteoarthritis (KOA). Methods: 80 patients with early KOA who were admitted to Shijiazhuang People's Hospital from June 2021 to December 2022 were selected, and patients were divided into control group (celecoxib, 40 cases) and observation group (tongzhi surunjiang capsules combined with celecoxib, 40 cases) by random number table method. The efficacy, pain visual analogue scale (VAS), Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score, inflammatory factors and pain mediators were compared between two groups. Results: The total effective rate in observation group was higher than that in control group(P<0.05). 1 month after treatment, the VAS and WOMAC scores in two groups decreased, and those in observation group were lower than control group at the same time point (P<0.05). 1 month after treatment, the levels of tumor necrosis factor-α (TNF-α), interleukin-1β(IL-1β) and interleukin-6 (IL-6) in two groups decreased, and those in observation group were lower than control group at the same time point (P<0.05). 1 month after treatment, prostaglandin E2 (PGE2) and substance P (SP) decreased in two groups, and those in observation group were lower than control group at the same time point(P<0.05). There was no significant difference in the incidence of adverse reactions between two groups(P>0.05). Conclusion: The combination of celecoxib and tongzhi surunjiang capsule in the treatment of early KOA patients can relieve pain, improve the clinical treatment effect, improve joint function, and also improve the levels of serum inflammatory factors and pain mediators.
查看全文   查看/发表评论  下载PDF阅读器
关闭